Question
What is a controlled master program with difference in conditions coverage, and when does a life sciences company need one?
Short answer
A controlled master program pairs locally admitted policies issued in each country where you need them with a master policy above them that fills the gap between narrow local terms and your home-country coverage. The difference in conditions and difference in limits elements are what close that gap. You typically need one once you have a foreign subsidiary, foreign employees, or a foreign manufacturing or collection site.
A necessary disambiguation
Difference in conditions means two different things in insurance, and this site uses both. In the directors and officers context, Side A difference in conditions is a policy that drops down when the company cannot or will not indemnify its directors. That is a governance instrument and it is covered in the D&O material.
This entry is about the international meaning: a master layer that sits over locally admitted policies and makes up the difference where local terms are narrower or local limits are lower than the home programme. Same three letters, unrelated instruments. Confirm which one a broker or a contract is referring to before acting on it.
Why local paper becomes necessary at all
A number of countries restrict or prohibit insurance written by carriers not licensed there. Where that applies, buying cover only on a US or UK policy is not just a thinner solution, it can create regulatory and premium tax problems, and it complicates paying a claim to a locally incorporated entity in local currency.
The other driver is practical rather than legal. Local counterparties, landlords, regulators, and public tenders frequently want evidence of insurance issued in their own market and language. Local paper is often what actually satisfies them.
The problem local paper creates
Locally admitted policies are written to local market terms. They are usually narrower than a comparable US or UK form and often carry lower limits, because they reflect what that market customarily sells rather than what your global risk profile requires.
That leaves a company with a set of policies that are compliant but inconsistent. A claim in one country gets treated meaningfully differently from the same claim elsewhere, which is exactly the outcome a life sciences board does not want when the exposure is a product or a trial subject.
How the master layer closes it
Difference in conditions addresses breadth. Where the local policy excludes something the master programme covers, the master responds, subject to its own terms and to what local law permits it to pay.
Difference in limits addresses adequacy. Where the local policy carries a limit below the programme standard, the master sits above it and brings the total up. Together they let a company hold compliant local paper without accepting the narrowest local terms as its true worldwide protection.
When a life sciences company crosses the threshold
The usual triggers are a foreign subsidiary or branch, employees based abroad rather than travelling, a manufacturing site or collection site outside the home country, or an EU Authorised Representative arrangement that carries shared liability.
Travelling staff alone generally do not require this structure. That exposure is usually handled through foreign voluntary workers compensation and business travel cover, which is a much lighter answer and is covered separately.
Related practice areas
Insurance clauses in this area
Related questions
- Does a US medical device liability policy cover claims from international sales?
- Does EU MDR compliance extend a US device maker’s products liability to EU claims?
- When does a life sciences company need foreign voluntary workers compensation coverage?
- What insurance does a US lab need to receive specimens from outside the United States?
Have a more specific question?
A specialist will reach out by the end of the day.
Request a free coverage review